{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:07:48Z","timestamp":1760854068706},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11886-019-1168-y","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T07:25:59Z","timestamp":1561706759000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes"],"prefix":"10.1007","volume":"21","author":[{"given":"Ajay Nair","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob S.","family":"Deyell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay Nair","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailin","family":"Barseghian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"11","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2337\/diacare.24.11.1936","volume":"24","author":"JP Boyle","year":"2001","unstructured":"Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24(11):1936\u201340.","journal-title":"Diabetes Care"},{"key":"1168_CR2","unstructured":"Statistics About Diabetes: American Diabetes Association\u00ae. \n                      http:\/\/www.diabetes.org\/diabetes-basics\/statistics\/\n                      \n                    . Accessed March 19, 2019."},{"key":"1168_CR3","unstructured":"Center for Health Statistics N. Table 19. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2016. 2017. \n                      https:\/\/www.cdc.gov\/nchs\/data\/hus\/2017\/019.pdf\n                      \n                    . Accessed 19 March 2019."},{"issue":"19","key":"1168_CR4","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease. JAMA. 1979;241(19):2035\u20138.","journal-title":"JAMA"},{"key":"1168_CR5","unstructured":"Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics a postmortem study. 2004. \n                      https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15142859\n                      \n                    . Accessed 19 March 2019."},{"issue":"5","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjmed.2003.10.016","volume":"116","author":"RW Nesto","year":"2004","unstructured":"Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004;116(5):11\u201322.","journal-title":"Am J Med"},{"issue":"5","key":"1168_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ejhf.797","volume":"19","author":"AA Tajik","year":"2017","unstructured":"Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the high-risk MI database. Eur J Heart Fail. 2017;19(5):635\u201342.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajh.10451","volume":"75","author":"VL Serebruany","year":"2004","unstructured":"Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40\u20137.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association AD","year":"2019","unstructured":"\u2022\u2022 American Diabetes Association AD. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103\u201323 The official recommendations of the ADA regarding antiplatelet therapy in DM.","journal-title":"Diabetes Care"},{"key":"1168_CR10","unstructured":"ACC endorses new ADA 2019 standards of medical care in diabetes - American College of Cardiology. \n                      https:\/\/www.acc.org\/latest-incardiology\/articles\/2018\/12\/17\/13\/34\/acc-endorses-new-ada-2019-standards-of-medical-care-in-diabetes\n                      \n                    . Accessed 19 March 2019."},{"key":"1168_CR11","unstructured":"Handelsman Y, Bloomgarden ZT, Grunberger G, et al. AACE\/ACE guidelines American Association of Clinical Endocrinologists and American College of Endocrinology-Clinical Practice guidelines for developing a diabetes mellitus comprehensive care plan-2015 AACE task force for developing a diabetes comprehensive care plan writing committee. Endocr Pract. 2015;21(1). \n                      https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25869408\n                      \n                    . Accessed 19 March 2019."},{"issue":"5","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/jc.2019-00198","volume":"104","author":"D LeRoith","year":"2019","unstructured":"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520\u201374.","journal-title":"J Clin Endocrinol Metab"},{"key":"1168_CR13","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339 Important, large-scale, well-designed trial that studed aspirin therapy in DM. \n                              \n                      https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1804988\n                      \n                    . Accessed 19 March 2019.","DOI":"10.1056\/NEJMoa1804988"},{"issue":"11","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.21037\/atm.2018.03.26","volume":"6","author":"R Casado-Arroyo","year":"2018","unstructured":"Casado-Arroyo R. Aspirin and diabetes mellitus in primary prevention: the endless conundrum. Ann Transl Med. 2018;6(11):218.","journal-title":"Ann Transl Med"},{"issue":"suppl 1","key":"1168_CR15","first-page":"S72","volume":"27","author":"JA Colwell","year":"2004","unstructured":"Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2004;27(suppl 1):S72\u20133.","journal-title":"Diabetes Care"},{"issue":"23","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"18","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","volume":"133","author":"IT Meredith","year":"2016","unstructured":"Meredith IT, Tanguay J-F, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, et al. Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study. Circulation. 2016;133(18):1772\u201382.","journal-title":"Circulation"},{"issue":"10","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68(10):1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"Investigators TG","year":"1993","unstructured":"Investigators TG. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673\u201382.","journal-title":"N Engl J Med"},{"issue":"23","key":"1168_CR20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"issue":"12","key":"1168_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jacc.2007.11.049","volume":"51","author":"S-W Lee","year":"2008","unstructured":"Lee S-W, Park S-W, Kim Y-H, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus. J Am Coll Cardiol. 2008;51(12):1181\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"1168_CR22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/eurheartj\/ehl423","volume":"28","author":"R Moreno","year":"2007","unstructured":"Moreno R, Fernandez C, Sanchez-Recalde A, Galeote G, Calvo L, Alfonso F, et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J. 2007;28(13):1583\u201391.","journal-title":"Eur Heart J"},{"issue":"19","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"issue":"23","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","volume":"67","author":"DL Bhatt","year":"2016","unstructured":"\u2022 Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in ischemic events with Ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS\u2013TIMI 54. J Am Coll Cardiol. 2016;67(23):2732\u201340 Sub-study from larger scale study assessing ticagrelor therapy in DM.","journal-title":"J Am Coll Cardiol"},{"key":"1168_CR25","unstructured":"BRILINTA\u2019s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes. \n                      https:\/\/www.astrazeneca-us.com\/content\/az-us\/media\/press-releases\/2019\/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-02252019.html\n                      \n                    . Accessed April 7, 2019."},{"issue":"20","key":"1168_CR26","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","volume":"25","author":"G Neriserneri","year":"2004","unstructured":"Neriserneri G, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25(20):1845\u201352.","journal-title":"Eur Heart J"},{"issue":"5","key":"1168_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ahj.2004.04.036","volume":"148","author":"GW Stone","year":"2004","unstructured":"Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute catheterization and urgent intervention triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148(5):764\u201375.","journal-title":"Am Heart J"},{"issue":"7329","key":"1168_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"key":"1168_CR29","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"1168_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000047786","volume":"13","author":"W Hacke","year":"2002","unstructured":"Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis. 2002;13(Suppl. 1):22\u20136.","journal-title":"Cerebrovasc Dis"},{"issue":"19","key":"1168_CR31","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","volume":"164","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations. Arch Intern Med. 2004;164(19):2106.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1168_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","volume":"72","author":"YD Wijeyeratne","year":"2011","unstructured":"Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011;72(4):647\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1168_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"20","key":"1168_CR34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3122\/jabfm.2012.03.100270","volume":"25","author":"J John","year":"2012","unstructured":"John J, Koshy SKG. Current oral antiplatelets: focus update on prasugrel. J Am Board Fam Med. 2012;25(3):343\u20139.","journal-title":"J Am Board Fam Med"},{"issue":"8","key":"1168_CR36","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/dc12-2510","volume":"36","author":"D Alexopoulos","year":"2013","unstructured":"Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, Tsoni E, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care. 2013;36(8):2211\u20136.","journal-title":"Diabetes Care"},{"issue":"7","key":"1168_CR37","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","volume":"32","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes MellitUS (OPTIMUS)-3 trial. Eur Heart J. 2011;32(7):838\u201346.","journal-title":"Eur Heart J"},{"issue":"18","key":"1168_CR38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","volume":"112","author":"JS Douglas","year":"2005","unstructured":"Douglas JS, Holmes DR, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112(18):2826\u201332.","journal-title":"Circulation"},{"issue":"5","key":"1168_CR39","first-page":"563","volume":"37","author":"Y Ikeda","year":"1987","unstructured":"Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung. 1987;37(5):563\u20136.","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"1168_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00005344-200408000-00017","volume":"44","author":"Y Liu","year":"2004","unstructured":"Liu Y, Cone J, Le SN, et al. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol. 2004;44(2):266\u201373.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1168_CR41","first-page":"93","volume":"3","author":"A Celestini","year":"2007","unstructured":"Celestini A, Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag. 2007;3(1):93\u20138.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"1168_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1046\/j.1365-2125.1996.00503.x","volume":"42","author":"M Milani","year":"1996","unstructured":"Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol. 1996;42(6):782\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1168_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0149-2918(02)85004-4","volume":"24","author":"TD Gladwell","year":"2002","unstructured":"Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002;24(1):38\u201358.","journal-title":"Clin Ther"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1168-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:45:58Z","timestamp":1593225958000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1168-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1168-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"78"}}